0001213900-23-037722.txt : 20230509 0001213900-23-037722.hdr.sgml : 20230509 20230509164510 ACCESSION NUMBER: 0001213900-23-037722 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230503 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 23902908 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISC STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea178217-8k_augmedixinc.htm CURRENT REPORT
0001769804 false 0001769804 2023-05-03 2023-05-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 3, 2023

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40890   83-3299164

(State or other jurisdiction

of incorporation)

  

(Commission File Number)

  

(I.R.S. Employer

Identification No.)

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 669-4885

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement

 

On May 3, 2023 (the “Effective Date”), Augmedix Operating Corp., a Delaware corporation (the “Company”), and subsidiary of Augmedix, Inc., entered into Statement of Work No. 2 (“SOW No.2”) with Dignity Health Medical Foundation (“DHMF”), to be effective as of March 15, 2023, and as a supplement to the Services Agreement, dated September 1, 2015, as amended, by and between CommonSpirit Health, a Colorado non-profit corporation. SOW No.2 permits DHMF to purchase Augmedix Notes for its Authorized Users (as defined in SOW No.2) by submitting a service order.

 

A copy of SOW No.2 is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of SOW No.2 does not purport to be complete and is qualified in its entirety by reference to the full text of SOW No.2.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1*   Statement of Work No.2, dated May 3, 2023, by and between Augmedix Operating Corp. f/k/a Augmedix, Inc. and DHMF.
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
*   Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Dated: May 9, 2023 By: /s/ Paul Ginocchio
  Paul Ginocchio
  Chief Financial Officer

 

 

2

 

 

 EX-10.1 2 ea178217ex10-1_augmedixinc.htm STATEMENT OF WORK NO.2, DATED MAY 3, 2023, BY AND BETWEEN AUGMEDIX OPERATING CORP. F/K/A AUGMEDIX, INC. AND DHMF

Exhibit 10.1

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

AUGMEDIX NOTES – STATEMENT OF WORK NO. 2

 

This Statement of Work (“SOW”), entered into by and between Dignity Health Medical Foundation (a Dignity Health Affiliate) (“DHMF” or “Client”) and Augmedix Operating Corp. (f/k/a Augmedix, Inc.) (“Augmedix”), is effective as of March 15, 2023 (the “SOW Effective Date”), and is a supplement to the Services Agreement, dated September 1, 2015, as amended (the “Agreement”) by and between CommonSpirit Health, a Colorado non-profit corporation, with a place of business at 3033 N. Ave., Phoenix, AZ 85013, and Augmedix, a Delaware corporation with its principal offices at 111 Sutter St., Suite 1300, San Francisco, CA 94104, and is hereby made a part of the Agreement. To the extent this SOW is inconsistent with the terms of the Agreement, the terms of the Agreement will prevail. All capitalized terms used in this SOW and not defined herein shall have the meaning assigned to such terms in the Agreement.

 

1.OVERVIEW AND DEFINITIONS

 

1.1. Authorized Users. This Statement of Work allows Client to onboard as many Authorized Users to Augmedix Notes as mutually agreed upon by the Parties. Client may purchase Augmedix Notes for its Authorized Users by signing and submitting an ordering document to Augmedix pursuant to this Statement of Work (each a “Service Order”). Augmedix shall make Augmedix Notes available to Client and its designated Authorized Users under this SOW during the Subscription Term indicated in the Service Order.

 

1.2. Definitions. As used in this SOW, all terms not otherwise defined in the Agreement or in this SOW shall have the meanings indicated in Appendix 1: Statement of Work Definitions attached hereto.

 

2.PARTIES’ RESPONSIBILITIES

 

2.1. Augmedix Responsibilities. Pursuant to each Service Order executed hereunder, Augmedix will perform the following Services:

 

2.1.1. Implementation and Deployment. Augmedix will coordinate and manage the implementation and deployment of Augmedix Notes on an Authorized User-by-Authorized User basis. During the initial deployment for each Authorized User, Augmedix will provide training to the Authorized User and for one or more MDSs working with the Authorized User such that Augmedix is able to satisfactorily complete and upload notes for patient visits for the Authorized User’s review and finalization.

 

2.1.2. Augmedix Notes. Augmedix will provide Augmedix Notes as specified herein and the applicable Service Order. Augmedix will prepare and upload medical notes into the Client’s Electronic Health Record (“Client EHR”), in pending status, awaiting the Authorized User’s review, finalization and approval. Augmedix will ensure that all MDSs comply with the terms and conditions of all agreements between Client and third parties relating to the use of the Client EHR software. Client may access and use Augmedix Notes solely for its internal business purposes and such access and use is expressly limited to the number of Authorized Users for which Client has paid Fees in accordance with the applicable Service Order.

 

1

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

2.1.3. Technology Maintenance. Augmedix will provide Client with one (1) Content Capture Device kit per Authorized User during the Subscription Term of the applicable Service Order. In the event an Authorized User desires additional Content Capture Device(s) to service additional Client Facilities, Client shall pay a monthly fee for such additional Client Facilities, as specified in the applicable Service Order. The Content Capture Devices and other hardware or materials provided for the purpose of delivering Augmedix Notes are owned (or leased) by Augmedix.

 

2.2. Client Responsibilities. Commencing on the SOW Effective Date, Client will have the following responsibilities:

 

2.2.1. IT, Telecommunications and Internet Services. Client acknowledges and agrees that Client’s and its Authorized Users’ use of Augmedix Notes is dependent upon access to telecommunications and Internet services meeting certain minimal site connectivity requirements. Except for the Content Capture Device(s) and Software, Client shall be solely responsible for acquiring and maintaining all telecommunications, Internet services, and other hardware and software required to access and use Augmedix Notes, including, without limitation, any and all costs, fees, expenses, and taxes of any kind related to the foregoing. Augmedix shall not be responsible for any loss or corruption of data, lost communications, or any other loss or damage of any kind arising from any such telecommunications and Internet services.

 

2.2.2. Access. At no cost to Augmedix, Client shall provide Augmedix (and any of its third-party MDS suppliers) with appropriate access and related credentials for use of the Client EHR, and any other required Client systems, as necessary for Augmedix to provide Augmedix Notes to Client. Client must provide all credentials and permissions necessary for Augmedix personnel to access the Client EHR within two (2) weeks of Augmedix’s written request. If credentials are not provided within two (2) weeks of Augmedix’s written request, Augmedix cannot guarantee Augmedix Notes Service will commence on schedule and reserves the right to delay an Authorized User’s Launch Date (as defined in Section 3.2.2 below) until appropriate Client EHR credentials are provided.

 

2.2.3. Recording of Patient Encounters. In order to enable Augmedix Notes, Authorized Users shall be responsible for initiating a recording on the Content Capture Device at the beginning of each patient-provider encounter and stopping the recording at the conclusion of the visit. For clarity, Authorized Users shall not record patient-provider encounters in a block of two or more visits; each patient-provider encounter shall be recorded separately. In the event an Authorized User fails to record each patient-provider encounter separately, Augmedix will make good faith efforts, but cannot guarantee, that patient notes will be available for review and finalization in the Client’s EHR within four (4) hours of the upload of a recording.

 

2.2.4. Patient Education and Consent. Client shall: (a) inform each patient, prior to an Authorized User’s use of Augmedix Notes with such patient, of the function, extent, and purpose of Augmedix Notes and utilization of audio/visual recording by means of the Content Capture Device in accordance with all applicable laws and regulations; and (b) obtain the patient’s consent, to the extent required under applicable laws and regulations, for the Authorized User to use Augmedix Notes. Without limiting the foregoing, Augmedix will provide Client with patient education materials, including FAQs, that Client may use to educate and obtain patient consent related to the use of the Augmedix Notes service (“Education Materials”). Client agrees not to make any material changes to the Education Materials without Augmedix’s prior written consent.

 

2

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

2.2.5. Scheduling. Seven (7) days prior to the Launch Date for an Authorized User and the start of each month thereafter, Client shall input a daily schedule for each Authorized User for each day of the following month in Client’s EHR or other scheduling software (“Daily Schedule”). The Daily Schedule will be used by Augmedix to staff MDSs for Augmedix Notes. If Client does not notify Augmedix seven (7) days in advance of clinic, Augmedix cannot guarantee MDS availability.

 

2.2.5.1 Client must provide seven (7) days’ written notice in advance of any material Daily Schedule change during a month. If less than seven (7) days’ written notice is received, Augmedix may not be able to accommodate such Daily Schedule change requests.

 

2.2.6. Feedback and Cooperation. Client’s Authorized Users shall provide cooperation and feedback to Augmedix and its MDSs as reasonably requested by Augmedix to fulfill its responsibilities in this Statement of Work.

 

2.3. Software and Equipment.

 

2.3.1. Software.

 

a) Subject to the terms and conditions of the Agreement, Augmedix hereby grants Client a non-exclusive, non-transferable, non-sublicensable right for Client and its Authorized Users to (a) access and use Augmedix Notes; (b) use the Software; and (c) use, copy, publish, and transmit the Documentation for Client’s internal purposes. For the avoidance of doubt, the Software may be used by Client on a concurrent-user basis to the extent necessary for Client to receive Augmedix Notes for the agreed-upon number of Authorized Users.

 

b) Restrictions. Without the prior written consent of Augmedix, Client shall not attempt to interfere with or disrupt Augmedix Notes or the Software or attempt to gain access to any systems or networks that connect thereto (except as required to access and use Augmedix Notes). Client shall not allow access to or use of Augmedix Notes by anyone other than Authorized Users. Client shall not: (a) copy, modify or distribute any portion of Augmedix Notes or the Documentation; (b) sell, rent, lease, lend, license, sublicense, distribute, or otherwise transfer Augmedix Notes or the Documentation to any third party; (c) decompile, disassemble or reverse engineer any portion of Augmedix Notes; (d) write or develop any derivative software or service based upon Augmedix Notes, the Documentation or any Augmedix Confidential Information; (e) use Augmedix Notes to provide processing or other services to third parties, or otherwise use Augmedix Notes on a “service bureau” basis; or (f) provide, disclose, divulge or make available to, or permit use of Augmedix Notes or Documentation by any third party without Augmedix’s prior written consent.

 

2.3.2. Provision of Hardware.

 

a) Subject to Client’s compliance with this Section 2.3.2, the acquisition, installation, configuration, and maintenance of the Content Capture Devices, including installation of all updates and other upgrades, will be solely the responsibility of Augmedix.

 

b) Client shall ensure that Authorized Users: (a) maintain the Content Capture Devices in good repair, condition and working order; and (b) use the Content Capture Devices in accordance with the applicable user manual(s) and guidelines provided from time to time by Augmedix. Upon receipt of a Content Capture Device, Client shall bear the entire risk of loss, damage, theft, or destruction of the Content Capture Device or any part thereof, from any and every cause whatsoever, which shall occur prior to the return of the Content Capture Devices to Augmedix, excluding reasonable wear and tear.

 

3

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

c) Client shall not: (a) sublease any of the Content Capture Devices; (b) create or incur, or permit to exist, any lien or encumbrance with respect to any of the Content Capture Device; (c) load any software other than the Software provided by Augmedix onto any Content Capture Device; (d) disable any protective safeguards; or (e) use the Content Capture Devices outside of the approved Client Facilities or for any purposes other than those set forth in this Agreement.

 

d) Upon the termination or expiration of the Agreement, Client will disconnect, package and return the Content Capture Devices to Augmedix in the same condition as when delivered to Client, ordinary wear and tear excepted. To the extent any Content Capture Device is damaged or not returned for any reason, Augmedix may invoice Client its reasonable costs for repair or replacement of such Content Capture Device and Client shall promptly pay such costs within [***] of receiving such invoice.

 

3.STATEMENT OF WORK SCHEDULE

 

3.1. Implementation. Upon execution of each Service Order, Augmedix will perform the following implementation services.

 

3.1.1. Authorized User Selection. To the extent practicable, Client’s designated Authorized Users should be identified in the applicable Service Order. To the extent not identified in a Service Order, Client shall provide a list of its selected Authorized Users to Augmedix no later than thirty (30) days prior to the first day Augmedix produces patient notes that are uploaded to the Client EHR for one or more Authorized Users. Augmedix will provide rolling guidance on the target Launch Date (as defined in Section 3.2.2. below) for each Authorized User.

 

3.1.2. Kick-off Call. Augmedix will initiate and conduct a kick-off call with Client to collect Authorized Users’ templates, macros and smartsets, discuss workflow and coordinate appropriate access to the Client EHR.

 

3.1.3. Technical Site Evaluation. Augmedix’s Site Connectivity Requirements are set forth on Appendix 2 hereto. To determine whether Client’s network infrastructure supports Augmedix Notes, Augmedix will assist remotely with a wireless network assessment on a mutually agreed upon date. If Augmedix determines Client’s network infrastructure fails to support Augmedix Notes, Client shall be responsible for the cost of any remediation necessary to enable its wireless network infrastructure to support Augmedix Notes. Alternatively, Augmedix may, subject to a viability assessment and Client’s approval, deliver Augmedix Notes via LTE mobile technology.

 

3.1.4. Augmedix Notes Deployment. Augmedix will coordinate and manage the deployment of Augmedix Notes on an Authorized User-by-Authorized User basis.

 

3.2. Service Phase.

 

3.2.1. The service phase (“Service Phase”) consists of ongoing virtual, non-real time medical documentation assistance by Augmedix-supplied MDSs on behalf of Client’s designated Authorized Users.

 

3.2.2. The Service Phase will commence on the first day Augmedix produces patient notes that are uploaded into the Client EHR, on an Authorized User-by-Authorized User basis (each a “Launch Date”), and continue for the remainder of the Subscription Term of the applicable Service Order.

 

4

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

4.FEES AND INVOCING

 

4.1. Fees. In consideration for providing Augmedix Notes, Client shall pay to Augmedix the Fees for its Subscription, in accordance with the terms set forth in the applicable Service Order.

 

4.2. Invoices; Payment; Late Payment. Augmedix shall invoice Client for Fees and applicable Taxes (if any) in the manner described in the applicable Service Order. All payments will be made in U.S. dollars. Each undisputed invoice is due and payable by Client no later than [***] following the invoice date. If Augmedix has not received payment within [***] after the due date, interest shall accrue on past due amounts at the rate of [***] per month, but in no event greater than the highest rate of interest allowed by law, calculated from the date such amount was due until the date that payment is received by Augmedix. Further, if any charge owing by Client is [***] or more overdue, Augmedix may, without limiting its other rights and remedies, suspend Services until such amounts are paid in full, provided that, Augmedix has given Client at least [***] notice that its account is overdue.

 

IN WITNESS WHEREOF, the Parties have caused this Statement of Work to be executed and delivered by their respective duly authorized representatives.

 

Dignity Health Medical Foundation   Augmedix Operating Corp. (f/k/a Augmedix, Inc.)
         
By:   /s/ Kelley Moore   By:   /s/ Manny Krakaris
         
Name:    Kelley Moore   Name:  Manny Krakaris
         
Title: System VP, IT Contracting & Vendor Management   Title:   CEO
         
Date: May 3, 2023   Date: May 3, 2023

 

5

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

Appendix 1

 

Statement of Work Definitions

 

(1) “Augmedix Notes” means the non-real time documentation product provided by Augmedix to Client pursuant to a Service Order, which such product includes virtual medical documentation assistance by remote Medical Documentation Specialist(s) for Authorized User(s) from recordings of patient-provider encounters and/or dictations, and the Content Capture Device(s) and the associated Software.

 

(2) “Authorized User(s)” means individual healthcare providers who are designated in writing to Augmedix as being authorized access to Augmedix Notes on Client’s behalf.

 

(3) “Client Facility(-ies)” means that/those certain designated Client facility or Client facilities designated in the applicable Service Order.

 

(4) “Content Capture Device(s)” that/those certain hardware device(s) provided by Augmedix to Client’s Authorized Users (e.g., smartphone) during the Subscription Term of the applicable Service Order to enable virtual, non-real time medical documentation assistance on behalf of Client.

 

(5) “Medical Documentation Specialist” (“MDS” or “MDSs”) means an Augmedix-supplied individual who provides virtual, non-real time medical documentation assistance for an Authorized User.

 

(6) “Software” means the software supplied and/or used by Augmedix to provide Augmedix Notes pursuant to the applicable Service Order.

 

(7) “Subscription” means the access to the Augmedix Notes Services purchased by Client on a per Authorized User basis.

 

(8) “Subscription Term” means the period identified in the Service Order during which Client’s Authorized User(s) is/are permitted to access and use Augmedix Notes on a per Authorized User basis.

 

6

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

Appendix 2

 

Site Connectivity Requirements

 

1. Internet Service Provider
   
    ● Cable or Fiber internet connectivity
       
2. Wireless Infrastructure
   
    ● Access Point (AP) model offers 802.11n or greater
       
    ● WPA2 PSK (AES) or WPA2 PEAP authentication
       
    ● PMK Key Caching enabled (CCKM also acceptable)
       
    ● DHCP required
       
3. Firewall Services and Ports
   
  Enable on the firewall, all outbound originated Augmedix network traffic, the requirements of which will be provided by Augmedix separately.

 

 

7

 

 

 EX-101.LAB 3 augx-20230503_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 augx-20230503_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 augx-20230503.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 03, 2023
Entity File Number 001-40890
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 888
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 ea178217-8k_augmedixinc_htm.xml IDEA: XBRL DOCUMENT 0001769804 2023-05-03 2023-05-03 iso4217:USD shares iso4217:USD shares 0001769804 false 8-K 2023-05-03 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 888 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea178217-8k_augmedixinc.htm augx-20230503.xsd augx-20230503_lab.xml augx-20230503_pre.xml ea178217ex10-1_augmedixinc.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea178217-8k_augmedixinc.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea178217-8k_augmedixinc.htm" ] }, "labelLink": { "local": [ "augx-20230503_lab.xml" ] }, "presentationLink": { "local": [ "augx-20230503_pre.xml" ] }, "schema": { "local": [ "augx-20230503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20230503", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea178217-8k_augmedixinc.htm", "contextRef": "From2023-05-03to2023-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://augmedix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea178217-8k_augmedixinc.htm", "contextRef": "From2023-05-03to2023-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-037722-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-037722-xbrl.zip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